VP Business Development at Evotec for contract API, drug product, preclinical development and integrated INDiGO IND packages inclusive of all three.
The continuous biomanufacturing process has very high yields equivalent to about 30 g/L compared to titers for batch fed single use bioreactors or bags.
Our J.POD Toulouse facility is launching later this year. It is the first fully #continuousbiomanufacturing for #antibodytherapeutics in Europe. Check out this short article on the #DCAT Value Chain Insights channel for more details! DCAT (Drug, Chemical & Associated Technologies Association)👨⚕️Philip Boehme Sarah Maxfield Nigel Shipston Christophe Martin
